The Director of Clinical Development at Cure Parkinson’s , Dr Richard Wyse, has been awarded an MBE in the King’s New Year’s Honours List.
Dr Wyse has received the honour for services to medicine in Parkinson’s disease.
Since Dr Wyse joined Cure Parkinson’s in 2007, he has created the International Linked Clinical Trials (iLCT) programme, which is considered to be ground-breaking in transforming how neurological research is carried out.
Its aim is to accelerate the development of new treatments with the potential to slow, stop or reverse Parkinson’s. Now run in partnership with Van Andel Institute in the US, it focuses on trialling drugs that have potential disease-modifying properties, many of which are already in use to treat other conditions. These are then evaluated and ranked by a committee of world-leading Parkinson’s specialists convened by Dr Wyse.
Since its creation, the iLCT has completed 20 clinical trials of new potential treatments for Parkinson’s, with 21 more trials ongoing, and many more in the pipeline.
Dr Wyse has also been instrumental in inspiring the first multi-arm trial in Parkinson’s, which commenced in Australia in 2020. Furthermore, on a voluntary basis, he regularly advises research-based organisations dealing with other neurodegenerative conditions.
Helen Matthews, CEO of Cure Parkinson’s, said: “We are so delighted that Richard’s vision, hard work, creative thinking, scientific skill and sheer determination to find a cure has been so deservedly recognised. His contribution to the field of Parkinson’s research is completely unique and has inspired so many. Congratulations, Richard!”
Parkinson’s Europe is sharing this article for information purposes only; it does not represent Parkinson’s Europe’s views and is not an endorsement by Parkinson’s Europe of any particular treatments, therapies or products.
